pamidronate has been researched along with Syndrome in 16 studies
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 6.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "Three children (ages 9 to 11 years) with osteoporosis pseudoglioma syndrome who had multiple vertebral collapse were treated over a 2-year period with intermittent intravenous bisphosphonate infusions (pamidronate in 2, clodronate in 1)." | 3.70 | Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. ( Cundy, T; Zacharin, M, 2000) |
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 2.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "Primary hyperparathyroidism is characterized by hypercalcemia with loss of bone mass." | 1.33 | Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. ( Kuo, SW; Lee, IT; Pei, D; Sheu, WH; Tu, ST, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, N | 1 |
| Reilly, RF | 1 |
| Whyte, MP | 1 |
| Madson, KL | 1 |
| Mumm, S | 1 |
| McAlister, WH | 1 |
| Novack, DV | 1 |
| Blair, JC | 1 |
| Helliwell, TR | 1 |
| Stolina, M | 1 |
| Abernethy, LJ | 1 |
| Shaw, NJ | 1 |
| Couturier, A | 1 |
| Aumaître, O | 1 |
| Gilain, L | 1 |
| Jean, B | 1 |
| Mom, T | 1 |
| André, M | 1 |
| Barros, ER | 1 |
| Dias da Silva, MR | 1 |
| Kunii, IS | 1 |
| Lazaretti-Castro, M | 1 |
| Andiran, N | 1 |
| Alikasifoglu, A | 1 |
| Alanay, Y | 1 |
| Yordam, N | 1 |
| Galadari, H | 1 |
| Bishop, AG | 1 |
| Venna, SS | 1 |
| Sultan, E | 1 |
| Do, D | 1 |
| Zeltser, R | 1 |
| Sweeney, SA | 1 |
| Kumar, VA | 1 |
| Tayar, J | 1 |
| Weber, DM | 1 |
| Safdar, A | 1 |
| Alonso, C | 1 |
| Hymes, S | 1 |
| Chatterjee, R | 1 |
| Shah, FT | 1 |
| Davis, BA | 1 |
| Byers, M | 1 |
| Sooranna, D | 1 |
| Bajoria, R | 1 |
| Pringle, J | 1 |
| Porter, JB | 1 |
| Bayram, F | 1 |
| Tanriverdi, F | 1 |
| Kurtoğlu, S | 1 |
| Atabek, ME | 1 |
| Kula, M | 1 |
| Kaynar, L | 1 |
| Keleştimur, F | 1 |
| Lee, IT | 1 |
| Sheu, WH | 1 |
| Tu, ST | 1 |
| Kuo, SW | 1 |
| Pei, D | 1 |
| Phadke, SR | 1 |
| Ramirez, M | 1 |
| DiFeo, A | 1 |
| Martignetti, JA | 1 |
| Girisha, KM | 1 |
| Davenport, A | 1 |
| Stearns, MP | 1 |
| Gurevich, Y | 1 |
| Poretsky, L | 1 |
| Collange, C | 1 |
| Brantus, JF | 1 |
| Sidot, C | 1 |
| Meunier, PJ | 1 |
| Berruti, A | 1 |
| Sperone, P | 1 |
| Fasolis, G | 1 |
| Torta, M | 1 |
| Fontana, D | 1 |
| Dogliotti, L | 1 |
| Angeli, A | 1 |
| Zacharin, M | 1 |
| Cundy, T | 1 |
1 review available for pamidronate and Syndrome
| Article | Year |
|---|---|
Hungry bone syndrome.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Diphosphonates; Hum | 2017 |
2 trials available for pamidronate and Syndrome
| Article | Year |
|---|---|
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabo | 2012 |
Torg-Winchester syndrome: lack of efficacy of pamidronate therapy.
Topics: Abnormalities, Multiple; Bone Density; Bone Density Conservation Agents; Bone Diseases, Developmenta | 2007 |
13 other studies available for pamidronate and Syndrome
| Article | Year |
|---|---|
Rapid skeletal turnover in a radiographic mimic of osteopetrosis.
Topics: Bone Remodeling; Child; Diphosphonates; Humans; Male; Osteoporosis; Osteosclerosis; Pamidronate; Rad | 2014 |
Craniofacial fibrous dysplasia: A 10-case series.
Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Child; Diagnosis, Differential; Diphospho | 2017 |
Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation.
Topics: Antineoplastic Agents; Blindness; Bone Density; Bone Density Conservation Agents; Child; Child, Pres | 2008 |
Cyclic pamidronate treatment in Bruck syndrome: proposal of a new modality of treatment.
Topics: Administration, Oral; Bone Density Conservation Agents; Calcitonin; Calcium Compounds; Clubfoot; Con | 2008 |
Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate.
Topics: Acneiform Eruptions; Diphosphonates; Drug Therapy, Combination; Humans; Hyperostosis; Isotretinoin; | 2009 |
Case 181: synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome.
Topics: Acne Vulgaris; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Biopsy; Contrast Media; Diagnosis, | 2012 |
Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Topics: Abnormalities, Multiple; Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Central | 2006 |
Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism.
Topics: Adult; Aged; Calcium; Clodronic Acid; Diphosphonates; Female; Humans; Hyperparathyroidism, Primary; | 2006 |
Administration of pamidronate helps prevent immediate postparathyroidectomy hungry bone syndrome.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypocalcemia; Male; Middle Aged; P | 2007 |
Possible prevention of hungry bone syndrome following parathyroidectomy by preoperative use of pamidronate.
Topics: Adenoma; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypocalcemia; Pamid | 2008 |
Sapho syndrome with femoral hyperostosis. Two case-reports.
Topics: Adult; Antirheumatic Agents; Diphosphonates; Female; Femur; Humans; Hyperostosis; Magnetic Resonance | 1996 |
Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancer.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Collagen; Diphosphonates; Human | 1997 |
Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates.
Topics: Analgesics, Non-Narcotic; Bone Density; Child; Clodronic Acid; Diphosphonates; Female; Fractures, Bo | 2000 |